Wright C L, Warsy A S, Holroyde M J, Trayer I P
Biochem J. 1978 Oct 1;175(1):125-35. doi: 10.1042/bj1750125.
The purification is described of rat hepatic hexokinase type III and kidney hexokinase type I on a large scale by using a combination of conventional and affinity techniques similar to those previously used for the purification of rat hepatic glucokinase [Holroyde, Allen, Storer, Warsy, Chesher, Trayer, Cornish-Bowden & Walker (1976) Biochem. J. 153, 363-373] and muscle hexokinase type II [Holroyde & Trayer (1976) FEBS Lett. 62, 215-219]. The key to each purification was the use of a Sepharose-N-aminoacylglucosamine affinity matrix in which a high degree of specificity for a particular hexokinase isoenzyme could be introduced by either varying the length of the aminoacyl spacer and/or varying the ligand concentration coupled to the gel. This was predicted from a study of the free solution kinetic properties of the various N-aminoacylglucosamine derivatives used (N-aminopropionyl, N-aminobutyryl, N-aminohexanoyl and N-aminooctanoyl), synthesized as described by Holroyde, Chesher, Trayer & Walker [(1976) Biochem. J. 153, 351-361]. All derivatives were competitive inhibitors, with respect to glucose, of the hexokinase reaction, and there was a direct correlation between the Ki for a particular derivative and its ability to act as an affinity matrix when immobilized to CNBr-activated Sepharose 4B. Muscle hexokinase type II could be chromatographed on the Sepharose conjugates of all four N-aminoacylglucosamine derivatives, although the N-aminohexanoylglucosamine derivative proved best. This same derivative was readily able to bind hepatic glucokinase and hexokinase type III, but Sepharose-N-amino-octanoyl-glucosamine was better for these enzymes and was the only derivative capable of binding kidney hexokinase type I efficiently. Separate studies with yeast hexokinase showed that again only the Sepharose-N-amino-octanoylglucosamine was capable of acting as an efficient affinity matrix for this enzyme. Implications of these studies in our understanding of affinity-chromatography operation are discussed.
采用与先前用于纯化大鼠肝脏葡萄糖激酶[霍尔罗伊德、艾伦、斯托勒、瓦尔西、切舍尔、特雷耶、康沃尔-鲍登和沃克(1976年)《生物化学杂志》153卷,363 - 373页]以及肌肉己糖激酶II型[霍尔罗伊德和特雷耶(1976年)《欧洲生物化学学会联合会快报》62卷,215 - 219页]类似的传统技术与亲和技术相结合的方法,大规模描述了大鼠肝脏III型己糖激酶和肾脏I型己糖激酶的纯化过程。每次纯化的关键在于使用琼脂糖 - N - 氨基酰基葡糖胺亲和基质,其中通过改变氨基酰基间隔臂的长度和/或改变偶联到凝胶上的配体浓度,可以引入对特定己糖激酶同工酶的高度特异性。这是根据对所使用的各种N - 氨基酰基葡糖胺衍生物(N - 氨基丙酰基、N - 氨基丁酰基、N - 氨基己酰基和N - 氨基辛酰基)的自由溶液动力学性质的研究预测的,这些衍生物是按照霍尔罗伊德、切舍尔、特雷耶与沃克[(1976年)《生物化学杂志》153卷,351 - 361页]所述合成的。所有衍生物都是己糖激酶反应中葡萄糖的竞争性抑制剂,并且特定衍生物的抑制常数(Ki)与其固定到溴化氰活化的琼脂糖4B上时作为亲和基质的能力之间存在直接相关性。肌肉己糖激酶II型可以在所有四种N - 氨基酰基葡糖胺衍生物的琼脂糖偶联物上进行色谱分离,尽管N - 氨基己酰基葡糖胺衍生物被证明是最好的。同样的这种衍生物能够很容易地结合肝脏葡萄糖激酶和III型己糖激酶,但是琼脂糖 - N - 氨基辛酰基葡糖胺对这些酶更好,并且是唯一能够有效结合肾脏I型己糖激酶的衍生物。对酵母己糖激酶的单独研究表明,同样只有琼脂糖 - N - 氨基辛酰基葡糖胺能够作为该酶的有效亲和基质。讨论了这些研究对我们理解亲和色谱操作的意义。